{"id":5671,"date":"2017-08-19T20:10:26","date_gmt":"2017-08-20T00:10:26","guid":{"rendered":"http:\/\/localhost:10028\/practiceareas\/actos-lawsuit\/"},"modified":"2022-06-21T16:54:07","modified_gmt":"2022-06-21T20:54:07","slug":"actos-dava","status":"publish","type":"practiceareas","link":"https:\/\/napolilaw.lemonadestand.org\/tr\/uygulama-alanlari-2\/actos-dava\/","title":{"rendered":"Actos Davas\u0131"},"content":{"rendered":"<h2 class=\"update-highlight\" style=\"text-align: center; background-color: red;\">ARTIK ACTOS VAKALARINI KABUL ETM\u0130YORUZ<\/h2>\n<h3><\/h3>\n<h3>Actos Nedeniyle Olu\u015fan Yaralanmalar \u0130\u00e7in Actos Davas\u0131 A\u00e7\u0131lmas\u0131 (Pioglitazone)<\/h3>\n<p>Actos (pioglitazone) is a treatment for type 2 diabetes. Available only by prescription, pioglitazone is in a class of medications called thiazolidinediones. Thiazolidinediones work in the body to balance the blood sugar by increasing the cells\u2019 receptiveness to insulin. Patients may have taken this drug under the brand name Actos or under other names such as Actoplus Met (pioglitazone and metformin) or Duetact (pioglitazone and glimepiride). People experiencing adverse side effects have begun filing actos lawsuits.<\/p>\n<p>More than two million Americans with type 2 diabetes take Actos. Many are increasingly concerned (and rightfully so) about potential side effects. Actos is the most prescribed medication for the treatment of type 2 diabetes, generating 3.4 billion in sales in 2009. However, recent studies have shown a link between this medication and bladder cancer. Some users are therefore considering their legal options in filing an Actos lawsuit against the manufacturer, Takeda Pharmaceuticals. With the serious side effects they have experienced, recovering financial compensation can make a significant difference in their ability to pay for medical care, lost earnings and other financial, physical and emotional losses or injuries.<\/p>\n<p>&nbsp;<\/p>\n<h3>Actos ile Ba\u011flant\u0131l\u0131 Ciddi Yan Etkiler<\/h3>\n<p>People taking this medication for treatment of type 2 diabetes should be aware that they are at risk for developing serious side effects, including new or worsening heart failure and liver problems. The government has also warned of pioglitazone and bladder cancer risks.<\/p>\n<p>The U.S. Food and Drug Administration (FDA) issued a warning in September of 2010 about Actos and bladder cancer after reviewing data from a ten-year study conducted by Takeda Pharmaceutical Company, the drug manufacturer. Data showed a link between Actos and bladder cancer. People taking the highest doses of the drug, or who had taken the drug for a long time, were at the highest risk of developing bladder cancer. Many of those victims have filed an Actos lawsuit.<\/p>\n<p><strong>Actos, mesane kanserine ek olarak zararl\u0131, kal\u0131c\u0131 veya ya\u015fam\u0131 tehdit edici ek riskler olu\u015fturabilir.<\/strong><\/p>\n<ul>\n<li><strong>Kemik K\u0131r\u0131\u011f\u0131 Riski \u2013 <\/strong>Actos, kemik k\u0131r\u0131lma riskini iki veya daha fazla kat art\u0131rabilir. Riskin kad\u0131nlarda daha fazla oldu\u011fu g\u00f6sterilmi\u015ftir, ancak erkekleri i\u00e7erebilir ve \u00e7o\u011funlukla kollarda, alt bacaklarda veya kal\u00e7alarda g\u00f6r\u00fcl\u00fcr ve muhtemelen Actos&#039;un kemik dokusunun b\u00fcy\u00fcmesi \u00fczerindeki etkisiyle ili\u015fkilidir.<\/li>\n<li><strong>Konjestif Kalp Yetmezli\u011fi \u2013 <\/strong>Actos kalp yetmezli\u011fi olas\u0131l\u0131\u011f\u0131n\u0131 ikiye katlayabilir. 2007&#039;den ba\u015flayarak, FDA, Konjestif Kalp Yetmezli\u011fi riskine dikkat \u00e7eken Actos bilgilerine bir &quot;kara kutu uyar\u0131s\u0131&quot; eklenmesini zorunlu k\u0131ld\u0131.<\/li>\n<li><strong>Kronik b\u00f6brek hastal\u0131\u011f\u0131 -<\/strong> Actos almak, b\u00f6brek hastal\u0131\u011f\u0131 riskini y\u00fczde 400&#039;e kadar art\u0131rabilir. B\u00f6brek hastal\u0131\u011f\u0131 y\u00fcksek tansiyona neden olur, kalp problemlerini k\u00f6t\u00fcle\u015ftirir ve b\u00f6brek replasman\u0131 veya \u00f6l\u00fcme neden olabilen son d\u00f6nem b\u00f6brek hastal\u0131\u011f\u0131 (ESRD) ile sonu\u00e7lanabilir.<\/li>\n<li><strong>Mak\u00fcler \u00f6dem - <\/strong>Makula \u00f6demi retina hasar\u0131na ve kal\u0131c\u0131 k\u00f6rl\u00fc\u011fe neden olabilir. Diyabetik hastalarda makula \u00f6demi riski daha fazlad\u0131r. 2009 y\u0131l\u0131nda yap\u0131lan bir ara\u015ft\u0131rma, ilac\u0131n makula \u00f6demi ve k\u00f6rl\u00fck geli\u015fme riskini ikiye katlad\u0131\u011f\u0131n\u0131 g\u00f6sterdi.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Haziran 2011&#039;de Frans\u0131z h\u00fck\u00fcmeti taraf\u0131ndan yap\u0131lan bir Actos ara\u015ft\u0131rmas\u0131n\u0131n sonu\u00e7lar\u0131 da Actos ile mesane kanseri aras\u0131nda bir ba\u011flant\u0131 buldu\u011funda, Fransa ve Almanya&#039;daki d\u00fczenleyiciler, ilac\u0131 piyasadan \u00e7eken bir Actos geri \u00e7a\u011f\u0131rma yay\u0131nlad\u0131. Yan\u0131t olarak FDA, ilac\u0131 tip 2 diyabetleri i\u00e7in alan insanlar\u0131 risk konusunda uyarmak i\u00e7in Actos yan etki etiketinde bir de\u011fi\u015fiklik yap\u0131lmas\u0131n\u0131 gerektirdi. FDA, ABD&#039;de bir Actos geri \u00e7a\u011f\u0131rmas\u0131 yay\u0131nlamad\u0131<\/p>\n<p>&nbsp;<\/p>\n<h3>Tehlikeli Belirtiler<\/h3>\n<p>Before the labeling change, patients taking Actos may not have known about or understood the link between Actos and bladder cancer, and this is why many are pursuing an Actos lawsuit. They may have even experienced potential symptoms of bladder cancer without realizing what they were or that they could have been linked to Actos use.<\/p>\n<p>Inform your doctor immediately if you took Actos for your type 2 diabetes and are experiencing such symptoms as:<\/p>\n<div class=\"two-col\">\n<ul>\n<li>\u0130drarda kan<\/li>\n<li>idrar aciliyeti<\/li>\n<li>\u0130drar yaparken a\u011fr\u0131<\/li>\n<li>S\u0131rt veya kar\u0131n a\u011fr\u0131s\u0131<\/li>\n<li>Yeni veya daha k\u00f6t\u00fc kalp yetmezli\u011fi;<\/li>\n<li>\u00d6dem;<\/li>\n<li>Karaci\u011fer sorunlar\u0131;<\/li>\n<li>Mesane kanseri;<\/li>\n<li>hipoglisemi;<\/li>\n<li>k\u0131r\u0131k kemikler\/k\u0131r\u0131klar;<\/li>\n<li>Mak\u00fcler \u00f6dem; Ve<\/li>\n<li>Yumurtlama hamileli\u011fe yol a\u00e7ar.<\/li>\n<\/ul>\n<\/div>\n<p>&nbsp;<\/p>\n<h3>Actos Davalar\u0131 \u2013 Bilmeniz Gerekenler<\/h3>\n<p>Victims of harm caused as a direct result of taking Actos have the right to take legal action against Takeda Pharmaceuticals. An Actos lawsuit may seek damages based on Takeda\u2019s negligence. These Actos lawsuits allege that Takeda failed to properly warn of the risks of taking Actos, continued to manufacture and market the drug despite known risks, manufactured a defective product, failed to properly test Actos, or\/and did not reveal Actos testing data to the public.<\/p>\n<p>There are class action lawsuits currently pending against Actos\u2019 manufacturer. You may have the right to join an existing Actos lawsuit, or file a civil action independently.<\/p>\n<p>Working with an Actos attorney will ensure that you have the information to properly present your case for damages in the Actos litigation.<\/p>\n<p>&nbsp;<\/p>\n<h3>\u00dccretsiz Vaka \u0130ncelemesi \u0130\u00e7in Ofisimizle \u0130leti\u015fime Ge\u00e7in<\/h3>\n<p>Tip 2 diyabet tedavisi i\u00e7in pioglitazon ald\u0131ysan\u0131z ve daha sonra doktorunuz size mesane kanseri te\u015fhisi koyduysa, Actos mesane kanseri davas\u0131 a\u00e7ma sebebiniz olabilir. \u0130la\u00e7 \u015firketi sizi Actos ve mesane kanseri aras\u0131ndaki ba\u011flant\u0131 konusunda yeterince uyarmam\u0131\u015f olabilir. Bu ilac\u0131 yanl\u0131\u015fl\u0131kla re\u00e7ete etmi\u015f olabilirsiniz. A <a href=\"\/tr\/uygulama-alanlari-2\/ilac-davasi\/\">ila\u00e7 davas\u0131<\/a> Napoli Shkolnik&#039;te avukat, PLLC, haklar\u0131n\u0131z\u0131 \u00f6\u011frenmeniz i\u00e7in size \u00fccretsiz bir hukuki dan\u0131\u015fmanl\u0131k sa\u011flayabilir. Avukatlar\u0131m\u0131z, hatal\u0131 re\u00e7eteli ila\u00e7lar nedeniyle yaralanan binlerce ki\u015fiye yard\u0131m etti. Actos davan\u0131zda sizi temsil etmek istiyoruz. Sizin i\u00e7in \u00f6nemli olan adalet ve tazminat i\u00e7in sava\u015fmak i\u00e7in ila\u00e7 \u015firketiyle u\u011fra\u015fmaktan korkmuyoruz. Yasal i\u015flem hakk\u0131n\u0131z hakk\u0131nda daha fazla bilgi edinmek i\u00e7in bug\u00fcn bizi aray\u0131n ve bir dava dan\u0131\u015fmanl\u0131\u011f\u0131 randevusu al\u0131n.<\/p>","protected":false},"excerpt":{"rendered":"<p>ARTIK ACTOS VAKALARINI KABUL ETM\u0130YORUZ Actos (Pioglitazone) Nedeniyle Olu\u015fan Yaralanmalar \u0130\u00e7in Actos Davas\u0131 A\u00e7mak Actos (pioglitazone) tip 2 diyabet tedavisidir. Sadece re\u00e7ete ile al\u0131nabilir,\u2026<\/p>","protected":false},"featured_media":0,"menu_order":49,"template":"","practiceareas_category":[743],"class_list":["post-5671","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5671\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media?parent=5671"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas_category?post=5671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}